scholarly journals Optimal Management of Chemotherapy-related Adverse Events

2020 ◽  
Vol 25 (1) ◽  
pp. 46-54
Author(s):  
Min Kyu Jung
Keyword(s):  
Adverse Events ◽  
Review Article ◽  
Optimal Management ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Pathogenetic Mechanism ◽  
Antiemetic Agent ◽  
Peripheral Polyneuropathy ◽  
Stimulating Factor

This review article deals with the optimal management of chemotherapy-related adverse events which are the nausea, vomiting, diarrhea, neutropenia, peripheral polyneuropathy. Recent literatures are reviewed and pathogenetic mechanism and management of each of adverse events are summarized. It is not simple but complexed and wide. Most patients could be expected how much they feel the nausea before the chemotherapy. We could prescribe several types of antiemetic agent efficiently. When the patients suffered from the neutropenia after previous chemotherapy, we should closely monitor their blood cell count. And we could help them after giving the granulocyte colony stimulating factor. Diarrhea is one of big troublesome issue related with chemotherapy. We could control the diarrhea by reducing the dose of the chemotherapy and prescribing optimally loperamide. Cisplatin and oxaliplatin could make the patients feel paresthesia and numbness but it’s hard to reverse or prevent even though we use anticonvulsants (carbamazepine, oxcarbazepine), antidepressants (amitriptyline, venlafaxine), amifostine, nimodipine, vitamins and minerals.

scholarly journals Granulocyte Colony-Stimulating Factor-Producing Bladder Cancer

2019 ◽  
Vol 12 (2) ◽  
pp. 603-607 ◽  
Author(s):  
Ryota Morinaga ◽  
Takashi Kawahara ◽  
Shinnosuke Kuroda ◽  
Yoshiaki Inayama ◽  
Hiroji Uemura
Keyword(s):  
Bladder Cancer ◽  
Blood Cell ◽  
Cell Count ◽  
Bladder Tumor ◽  
Resected Specimen ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Gross Hematuria ◽  
Stimulating Factor

Granulocyte colony-stimulating factor (G-CSF)-producing bladder cancer is rare, with only 75 cases reported in Japan. A 67-year-old woman was referred to our institution for the further examination of gross hematuria. Cystoscopy revealed a 7-cm bladder tumor. The initial white blood cell count was 17,100/μL, and a transurethral resected specimen showed G-CSF expression. CT revealed that the tumor had invaded the colon. As the patient had uncontrollable schizophrenia, radical cystectomy was abandoned. We herein report a case of G-CSF-producing bladder tumor.

Stimulatory effects of granulocyte colony-stimulating factor on colony- forming units-spleen (CFU-S) differentiation and pre-CFU-S proliferation in mice

Blood ◽  
1991 ◽  
Vol 77 (12) ◽  
pp. 2597-2602 ◽  
Author(s):  
T Tanaka ◽  
T Suda ◽  
J Suda ◽  
T Inoue ◽  
Y Hirabayashi ◽  
...  
Keyword(s):  
Mouse Bone Marrow ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Colony Forming Units ◽  
Immature Myeloid Cells ◽  
Polymerase Chain ◽  
Buffer Control ◽  
Macrophage Colony ◽  
Stimulating Factor

Abstract Granulocyte colony-stimulating factor (G-CSF) was reported to increase the number of colony-forming units-spleen (CFU-S) and multilineage colonies as well as myeloid-committed cells. We investigated the effects of G-CSF on myeloid progenitors and primitive stem cells in a mouse bone marrow transplantation (BMT) system. Lethally irradiated mice received BM cells from untreated or 5-fluorouracil-treated mice, and then were administered G-CSF or carrier buffer (control) for 5 days from immediately after BMT. A pre-CFU-S assay was performed by the repeated transplantation of BM cells from the first BMT recipients to other mice. By the method of polymerase chain reaction, most of the spleen colonies in the secondary recipients were confirmed to be derived from the first donors. G-CSF did not increase the peripheral white blood cell count significantly, but did increase the number of immature myeloid cells and granulocyte-macrophage colony-forming cells in the BM. The number of erythroid cells in the BM was initially suppressed and then increased by G-CSF treatment. In addition, the pre- CFU-S assay showed an increase in pre-CFU-S cells due to G-CSF administration. The number of spleen colonies of first BMT recipients did not increase, but a higher percentage of them were committed to a certain lineage by G-CSF treatment. These findings suggest that G-CSF has important roles in the early stages of hematopoiesis.

scholarly journals Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

Blood ◽  
2014 ◽  
Vol 123 (23) ◽  
pp. 3655-3663 ◽  
Author(s):  
Michael A. Pulsipher ◽  
Pintip Chitphakdithai ◽  
Brent R. Logan ◽  
Willis H. Navarro ◽  
John E. Levine ◽  
...  
Keyword(s):  
Adverse Events ◽  
Lower Risk ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Serious Adverse Events ◽  
Increased Risk ◽  
Key Points ◽  
Life Threatening ◽  
Stimulating Factor

Key Points BM donors have a threefold higher risk for life-threatening, serious unexpected, or chronic adverse events vs PBSC donors (0.99% vs 0.31%). Donors receiving granulocyte colony-stimulating factor for PBSC collection had no evidence of increased risk for cancer, autoimmune illness, and stroke.

Growth and reproductive traits of F1-generation transgenic goats for human granulocyte-colony stimulating factor

2018 ◽  
Vol 58 (7) ◽  
pp. 1218
Author(s):  
R. I. T. P. Batista ◽  
J. M. G. Souza-Fabjan ◽  
D. Í. A. Teixeira ◽  
L. M. Melo ◽  
V. J. F. Freitas
Keyword(s):  
Blood Cell ◽  
Cell Count ◽  
White Blood Cell Count ◽  
White Blood Cell ◽  
Reproductive Parameters ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Transgenic Lines ◽  
Stimulating Factor

To ensure that animal welfare requirements and phenotypic characteristics of the newly produced transgenic lines are not compromised, an evaluation of all individuals is necessary. This can be inferred by the analysis of the growth and reproduction parameters. The present study was designed to determine the impact of the insertion of human granulocyte-colony stimulating factor (hG-CSF) transgene on growth and reproductive characteristics in first-generation (F1) goats from two transgenic lines. Bodyweight (BW) development (BW at birth, mean BW gain before weaning, BW at weaning, mean BW gain after weaning, BW at puberty), as well as reproductive parameters (age at puberty, ejaculate volume, concentration, total sperm per ejaculate, massal motility, progressive individual motility, major and minor defects) were similar (P > 0.05) between transgenic (T) and non-transgenic (NT) goats. Significant (P < 0.05) differences in mean (±s.d.) white blood cell count were observed between T and NT in first day of life (174.6 ± 14.7 × 103 and 15.0 ± 4.0 × 103 cells/µL), and during (66.8 ± 21.1 × 103 and 17.0 ± 4.6 × 103 cells/µL) and after (36.6 ± 4.0 × 103 and 15.5 ± 2.2 × 103 cells/µL) suckling, even though hG-CSF has not been detected in blood serum in any analysis. Although other cell counts were occasionally higher in T animals, differential counts showed that this difference was mainly due to an increased number of neutrophils, which represents 84.6%, 67.2% and 56.8% of total white blood cell count respectively, in the three time periods. Kidney and liver biochemical analyses indicated that all goats were healthy. Thus, it is possible to assume that all animals are normal and had no deleterious effects on either growth or reproductive parameters by the presence of transgene or as a consequence of leukocyte profile alteration.

scholarly journals Safety of adjuvant gemcitabine plus cisplatin chemotherapy in a patient with bilateral ureteral cancer undergoing hemodialysis

2021 ◽  
Author(s):  
Yumiko Goto ◽  
Kent Kanao ◽  
Kazuhiro Matsumoto ◽  
Ikuo Kobayashi ◽  
Keishi Kajikawa ◽  
...  
Keyword(s):  
Side Effects ◽  
Adverse Events ◽  
Standard Dose ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Old Japanese ◽  
Left And Right ◽  
The Common ◽  
Grade 3 ◽  
Stimulating Factor

AbstractAn 80 year old Japanese man with bilateral ureteral cancer underwent laparoscopic bilateral nephroureterectomy and lymph-node dissection. The pathological stage of the left and right ureteral tumors was pT3pN0M0. He received two courses of adjuvant gemcitabine and cisplatin chemotherapy while undergoing hemodialysis. The standard dose of gemcitabine and 50% of the standard dose of cisplatin were administered on the same day. Hemodialysis was started 6 h after gemcitabine administration and 1 h after cisplatin administration. The side effects were evaluated according to the Common Terminology Criteria for Adverse Events v4.0. In the first course, Grade 4 side effects including leukopenia, neutropenia, and thrombocytopenia were observed. He was treated with granulocyte colony-stimulating factor and platelet transfusion. Because the second course was administered without reducing the doses, granulocyte colony-stimulating factor was administered prophylactically, and Grade 4 side effects were reduced to Grade 3. Gemcitabine plus cisplatin chemotherapy can be administered safely in a patient with advanced ureteral cancer undergoing hemodialysis by adequately managing adverse events.

scholarly journals Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: A single-center retrospective study

2020 ◽  
Author(s):  
Kitagawa Yusuke ◽  
Hiroki Osumi ◽  
Eiji Shinozaki ◽  
Yumiko Ota ◽  
Izuma Nakayama ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Polyethylene Glycol ◽  
Adverse Events ◽  
Metastatic Colorectal Cancer ◽  
Progression Free Survival ◽  
Severe Neutropenia ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Grade 3 ◽  
Stimulating Factor

Abstract Background: This study aimed to evaluate the efficacy and safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice. Methods: We retrospectively analyzed mCRC patients who received FOLFOXIRI plus Bev between December 2015 and December 2017. We evaluated the efficacy of PEG-G-CSF as preventing or treating grade 3/4 neutropenia, the overall response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors version 1.1, progression-free survival (PFS), overall survival (OS), and adverse events of FOLFOXIRI plus Bev based on the Common Terminology Criteria for Adverse Events version 4.0. Results A total of 26 patients (median age 53.5 years) were included. The ORR rate was 65.3%, the median PFS was 9.6 months (7.2–16.9), and the median OS was 24.2 months (13.6–NA). Grade 3 or 4 neutropenia occurred in 53.8% of the patients, and febrile neutropenia occurred in 7.7%. PEG-G-CSF was given to 77.0% of the patients, including prophylactically (n = 9) and after the development of grade 3 or 4 neutropenia (n = 11). No patients experienced grade 3 or higher neutropenia after the administration of PEG-G-CSF. In seven of the nine patients who received PEG-G-CSF prophylactically (77.8%), no dose adjustment was required. Conclusions PEG-G-CSF is useful in preventing severe neutropenia in mCRC patients treated with FOLFOXIRI plus Bev.

scholarly journals Stimulatory effects of granulocyte colony-stimulating factor on colony- forming units-spleen (CFU-S) differentiation and pre-CFU-S proliferation in mice

Blood ◽  
1991 ◽  
Vol 77 (12) ◽  
pp. 2597-2602
Author(s):  
T Tanaka ◽  
T Suda ◽  
J Suda ◽  
T Inoue ◽  
Y Hirabayashi ◽  
...  
Keyword(s):  
Mouse Bone Marrow ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Colony Forming Units ◽  
Immature Myeloid Cells ◽  
Polymerase Chain ◽  
Buffer Control ◽  
Macrophage Colony ◽  
Stimulating Factor

Granulocyte colony-stimulating factor (G-CSF) was reported to increase the number of colony-forming units-spleen (CFU-S) and multilineage colonies as well as myeloid-committed cells. We investigated the effects of G-CSF on myeloid progenitors and primitive stem cells in a mouse bone marrow transplantation (BMT) system. Lethally irradiated mice received BM cells from untreated or 5-fluorouracil-treated mice, and then were administered G-CSF or carrier buffer (control) for 5 days from immediately after BMT. A pre-CFU-S assay was performed by the repeated transplantation of BM cells from the first BMT recipients to other mice. By the method of polymerase chain reaction, most of the spleen colonies in the secondary recipients were confirmed to be derived from the first donors. G-CSF did not increase the peripheral white blood cell count significantly, but did increase the number of immature myeloid cells and granulocyte-macrophage colony-forming cells in the BM. The number of erythroid cells in the BM was initially suppressed and then increased by G-CSF treatment. In addition, the pre- CFU-S assay showed an increase in pre-CFU-S cells due to G-CSF administration. The number of spleen colonies of first BMT recipients did not increase, but a higher percentage of them were committed to a certain lineage by G-CSF treatment. These findings suggest that G-CSF has important roles in the early stages of hematopoiesis.

667 PEGYLATED RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR IN DEFINITIVE CHEMORADIOTHERAPY OF ESOPHAGEAL CANCER: PRELIMINARY RESULTS

2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Hongcheng Zhu ◽  
Huijun Zhu ◽  
Dashan Ai ◽  
Yun Chen ◽  
Qi Liu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Locally Advanced ◽  
Concurrent Chemotherapy ◽  
Control Group ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blood Cell Count ◽  
Definitive Chemoradiotherapy ◽  
Neutrophil Recovery ◽  
Stimulating Factor

Abstract   To compare the efficiency and safety of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF), on the risk of neutropenia in patients with esophageal squamous cell carcinoma (ESCC) of definitive chemoradiotherapy (dCRT). Methods ESCC patients receiving dCRT in our hospital were adopted in this study. Patients in the PEG-rhG-CSF group were treated with preventive PEG-rhG-CSF 6 mg subcutaneously at 24–48 h after completion of chemotherapy of each cycle, while the control group was not. The usage of rhG-CSF was permitted when the absolute neutrophil count (ANC) ≤2 × 109/L, or white blood cell count (WBC) ≤3 × 109/L. Results A total of 34 ESCC patients were in the PEG-rhG-CSF group and 41 were in the control group. Improved chemotherapy cycle completion and radiation dose completion were identified in the PEG-rhG-CSF group (P &lt; 0.001). Leukocyte recovery and neutrophil recovery, (P &lt; 0.001). PEG-rhG-CSF reduced incidence of neutropenia, and time to ANC recovery in different chemotherapy cycles, with (Cycle 1–2, P &lt; 0.001 ~ P = 0.02) or without RT (Cycle 3–4, P = 0.04 ~ P = 0.8799). Antibiotics utilization rates were significantly higher in the PEG-rhG-CSF group during concurrent chemotherapy with RT, but not during consolidative CRT (Cycle 3 and Cycle 4: P &gt; 0.05). Conclusion PEG-rhG-CSF prescribed as prophylaxis reduces acute toxicities by concurrent CRT and contributes to completion of dCRT regime in locally advanced ESCC therapeutics. The significance was not observed in chemotherapy alone without RT in the current findings.

Sign in / Sign up

Export Citation Format

Share Document